Analytical and Potential Clinical Performance of Oncomine Myeloid Research Assay for Myeloid Neoplasms

Park, Joonhong; Kim, Hoon Seok; Lee, Jong-Mi; Jung, Jae-Hun; Kang, Dain; Choi, Hayoung; Lee, Gun Dong; Son, Jungok; Park, Silvia; Cho, Byung-Sik; Kim, Hee-Je; Kim, Seongkoo; Lee, Jae Woo; Chung, Nack‐Gyun; Cho, Bin; Zhang, Hua; Khazanov, Nickolay A.; Choi, Jongpill; Jung, Jae-Won; Kim, Yonggoo; Kim, Myungshin

doi:10.1007/s40291-020-00484-5

Cited by 6 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genomic DNA was extracted from the BM aspirates with the QIAamp DNA Mini Kit (Qiagen, Hamburg, Germany). For detection of genetic mutation, next-generation sequencing (NGS) was performed using a customized St. Mary’s customized NGS panel for acute leukemia (SM acute leukemia panel) including 67 genes, 33 , 34 while the detection of FLT3 -ITD mutation, polymerase chain reaction (PCR) for fragment analysis was performed using a modified protocol as previously described. 35 – 38 The mutation results used in this study almost ( n = 98, 68.5%) relied on initial NGS results except for patients with available NGS results at relapse.…”

Section: Methodsmentioning

confidence: 99%

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

Park

Kwag

Lee

et al. 2022

Therapeutic Advances in Hematology

Self Cite

View full text Add to dashboard Cite

Background: Evidence that a venetoclax (VEN)-combined regimen is effective in relapsed/refractory acute myeloid leukemia (R/R AML) is emerging. However, it is unknown how VEN-combined low intensity treatment compares to intensive chemotherapy (IC) in medically fit patients with R/R AML. Methods: We compared AML patients who received IC ( n = 89) to those who received a VEN in combination with hypomethylating agents or low dose cytarabine (VEN combination) ( n = 54) as their first- or second-line salvage after failing anthracycline-containing intensive chemotherapy. Results: The median age was 49 years, and significantly more patients in the VEN combination group were in their second salvage and had received prior stem cell transplantation (SCT). Overall response rates including CR, CRi, and MLFS were comparable (44.0% for IC vs. 59.3% for VEN combination, p = 0.081), but VEN combination group compared to IC group tended to show lower treatment related mortality. The rate of bridging to SCT was the same (68.5%), but the percentage of SCT at blast clearance was significantly higher in the VEN-combined group (62.3% vs. 86.5%, p = 0.010). After median follow-up periods of 22.5 (IC) and 11.3 months (VEN combination), the median overall survival was 8.9 (95% CI, 5.4-12.4) and 12.4 months (95% CI, 9.5-15.2) ( p = 0.724), respectively. Conclusion: VEN combination provides a comparable anti-leukemic response and survival to salvage IC, and provide a bridge to SCT with better disease control in medically-fit patients with R/R AML.

show abstract

Section: Methodsmentioning

confidence: 99%

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

Park

Kwag

Lee

et al. 2022

Therapeutic Advances in Hematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…NGS analysis was performed using St. Mary’s customized NGS panel for acute leukemia, i.e., the “SM Acute leukemia panel.” Ion AmpliSeq Technology (Thermo Fisher Scientific) was used to amplify 67 genes (Supplementary Table S2 ) using an Ion Chef™ system (Thermo Fisher Scientific) and an Ion S5 XL Sequencer (Thermo Fisher Scientific) 16 .…”

Section: Methodsmentioning

confidence: 99%

Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia

Kim

Kang

et al. 2021

Blood Cancer J.

Self Cite

View full text Add to dashboard Cite

Given limited studies on next-generation sequencing-based measurable residual disease (NGS-MRD) in acute myeloid leukemia (AML) patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT), we longitudinally collected samples before and after allo-HSCT from two independent prospective cohorts (n = 132) and investigated the prognostic impact of amplicon-based NGS assessment. Persistent mutations were detected pre-HSCT (43%) and 1 month after HSCT (post-HSCT-1m, 20%). All persistent mutations at both pre-HSCT and post-HSCT-1m were significantly associated with post-transplant relapse and worse overall survival. Changes in MRD status from pre-HSCT to post-HSCT-1m indicated a higher risk for relapse and death. Isolated detectable mutations in genes associated with clonal hematopoiesis were also significant predictors of post-transplant relapse. The optimal time point of NGS-MRD assessment depended on the conditioning intensity (pre-HSCT for myeloablative conditioning and post-HSCT-1m for reduced-intensity conditioning). Serial NGS-MRD monitoring revealed that most residual clones at both pre-HSCT and post-HSCT-1m in patients who never relapsed disappeared after allo-HSCT. Reappearance of mutant clones before overt relapse was detected by the NGS-MRD assay. Taken together, NGS-MRD detection has a prognostic value at both pre-HSCT and post-HSCT-1m, regardless of the mutation type, depending on the conditioning intensity. Serial NGS-MRD monitoring was feasible to compensate for the limited performance of the NGS-MRD assay.

show abstract

“…Overall, high-throughput approaches, and NGS in particular, are essential for the analysis of genomic alterations during the diagnosis, treatment, and follow-up of patients with AML. Although this is a sensitive, informative technique its high turnaround time might be a limitation for its use [22].…”

Section: Discussionmentioning

confidence: 99%

The role of next-generation sequencing in acute myeloid leukemia

Llop

Sargas

Barragán

2022

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewThe development of high-throughput techniques like next-generation sequencing (NGS) has unraveled the genetic profile of cancer. In this review, we discuss the role of NGS on the diagnostic, risk stratification, and follow-up of patients with acute myeloid leukemia (AML).Recent findingsNGS has become an essential tool in clinical practice for AML management. Therefore, efforts are being made to improve its applications, automation, and turnaround time. Other high-throughput techniques, such as whole genome sequencing or RNA-sequencing, can be also used to this end. However, not all institutions may be able to implement these approaches. NGS is being investigated for measurable residual disease (MRD) assessment, especially with the development of error-correction NGS. New data analysis approaches like machine learning are being investigated in order to integrate genomic and clinical data and develop comprehensive classifications and risk scores.SummaryNGS has proven to be a useful approach for the analysis of genomic alterations in patients with AML, which aids patient management. Current research is being directed at reducing turnaround time and simplifying processes so that these techniques can be universally integrated into clinical practice.

show abstract

Analytical and Potential Clinical Performance of Oncomine Myeloid Research Assay for Myeloid Neoplasms

Cited by 6 publications

References 30 publications

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia

The role of next-generation sequencing in acute myeloid leukemia

Contact Info

Product

Resources

About